微小残存病変検査市場：技術別、用途別、エンドユーザー別、地域別

微小残存病変検査市場は、2024年には23億1,000万米ドルと推定され、2031年には49億7,000万米ドルに達すると予測され、2024年から2031年までのCAGRは11.6%です。

図.微小残存病変検査市場シェア（%）、2024年地域別

微小残存病変（MRD）検査では、初回治療後に体内に残存する可能性のある微量のがん細胞を検出します。MRD検査は、血液専門医と腫瘍専門医の双方にとって、治療効果をモニタリングし、患者の転帰を予測するための重要なツールです。MRD検査により、医師は他の方法よりも早期に疾患再発のリスクが高い患者を特定することができます。これにより、追加の治療やより詳細なモニタリングが必要かどうかを判断することができます。MRDを高感度で検出するために、マルチパラメーターフローサイトメトリー、対立遺伝子特異的オリゴヌクレオチド定量PCR、次世代シーケンシングなどのいくつかの技術が使用されています。さまざまなタイプの血液がんにおけるMRD検査の応用が拡大し、技術も向上していることから、市場は今後数年間で大きな成長を遂げることが予想されます。

市場力学：

世界の微小残存病変検査市場は、血液がんの罹患率の上昇、治療モニタリングにおけるMRD検査の採用増加、医師の意識の高まりによって牽引されています。しかし、熟練した専門家の不足、検査方法の高指数化、一部の地域における償還の問題が市場の成長を抑制しています。感度が向上し、自動化されたプラットフォームを備えた様々な新製品が各社から発売されており、これが主なビジネスチャンスとなっています。例えば、個別化治療やリキッドバイオプシー技術は新たな分野です。企業と研究機関の共同研究も、新たな地域への市場拡大を後押ししています。COVID-19パンデミックのヘルスケアリソースへの影響は課題であるが、現在のシナリオでは遠隔医療と在宅サンプル採取がMRDモニタリングの継続性を支援しています。

本調査の主な特徴

• 本レポートでは、世界の微小残存病変検査市場を詳細に分析し、2023年を基準年とした予測期間（2024-2031年）の市場規模と年間平均成長率（CAGR%）を掲載しています。
• さまざまなセグメントにおける潜在的な収益成長機会を明らかにし、この市場に対する魅力的な投資提案のマトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
• 本レポートでは、企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の微小残存病変検査市場の主要企業をプロファイルしています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の微小残存病変検査市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の微小残存病変検査市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 疫学
• 最近の動向
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の微小残存病変検査市場：COVID-19パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の微小残存病変検査市場：技術別、2019年-2031年

• フローサイトメトリー
• ポリメラーゼ連鎖反応（PCR）
• その他

第6章 世界の微小残存病変検査市場：用途別、2019年-2031年

• リンパ腫
• 固形腫瘍
• その他

第7章 世界の微小残存病変検査市場：エンドユーザー別、2019年-2031年

• 病院
• クリニック
• 調査室
• その他

第8章 世界の微小残存病変検査市場：地域別、2019年-2031年

第9章 競合情勢

• 企業プロファイル
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Adaptive Biotechnologies
  • Invitae Corporation
  • ASURAGEN, INC.
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Natera, Inc.
  • Sysmex Inostics, Inc.
  • Amgen Inc.
  • FOUNDATION MEDICINE, INC.
  • Sebia
  • Myriad Genetics, Inc.

第10章 アナリストの視点

• アナリストの見解
• 一貫した機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.

Figure. Minimal Residual Disease Testing Market Share (%), By Region 2024

Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.

Market Dynamics:

The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.

Key Features of the Study:

• This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market

Detailed Segmentation-

• Technology:
  • Flow Cytometry
  • Polymerase chain reaction (PCR)
  • Next generation sequencing
• Application:
  • Lymphoma
  • Solid Tumors
  • Others
• End User:
  • Hospitals
  • Clinics
  • Research Laboratories
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bio-Rad Laboratories, Inc.
  • Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Adaptive Biotechnologies
  • Invitae Corporation
  • ASURAGEN, INC.
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Natera, Inc.
  • Sysmex Inostics, Inc.
  • Amgen Inc.
  • FOUNDATION MEDICINE, INC.
  • Sebia
  • Myriad Genetics, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Technology
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Epidemiology
• Recent Developments
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Minimal Residual Disease Testing Market, By Technology, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Flow Cytometry
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Polymerase chain reaction (PCR)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Minimal Residual Disease Testing Market, By Application, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Solid Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Minimal Residual Disease Testing Market, By End User, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Research Laboratories
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Minimal Residual Disease Testing Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Bio-Rad Laboratories, Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Adaptive Biotechnologies
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Invitae Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • ASURAGEN, INC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Invivoscribe, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Laboratory Corporation of America Holdings
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Natera, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sysmex Inostics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • FOUNDATION MEDICINE, INC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sebia
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Myriad Genetics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact